Taxonomy
New, Potentially Treatable, Type of CMT Discovered
A team led by Dr. Stephan Züchner at the University of Miami has discovered a new type of Charcot-Marie-Tooth (CMT) disease that may be treatable with drugs already approved for other diseases. CMT2E Gene Therapy Project Approved
The CMTA Board of Directors approved a $265,000 research project for CMT2E that aims to advance CMT2E gene therapy by demonstrating positive results for axonal forms of CMT affecting motor neurons.The 2020 Spring CMTA Report
In a world turned upside down, The CMTA Report continues to bring you help for today and hope for tomorrow. In this issue you’ll find helpful stories on tendon transfers, HNPP and nerve conduction studies, as well as hopeful news on recently funded research projects.CMTA Board Approves CMT1B Project
The CMTA Board of Directors approved a new research project aimed at developing biomarkers for CMT1B to aid in the collection of natural history data critical to clinical trials.Coronavirus (COVID-19) and CMT
The CMTA is aware that the coronavirus (COVID-19) may have more of an impact on people and families who are at higher risk of infection, so we are reaching out to share resources and ensure you are informed.CMTA Event Schedule Update from CEO Amy Gray
The CMTA has decided to postpone and/or reschedule all upcoming CMTA branch meetings, events and walks originally scheduled to occur in March through May of 2020.Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease
ACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo; Acceleron to discontinue development of ACE-083.Coronavirus (COVID-19) Update
The Centers for Disease Control and Prevention (CDC) is responding to an outbreak of respiratory disease caused by a novel (new) coronavirus that was first detected in China. CMTA Funds Cutting-Edge Gene Editing Studies for Type 2 CMT
Drs. Bruce Conklin and Luke Judge will use a $653,000 grant from the CMTA to develop the gene-editing technique known as CRISPR for application to CMT2A, 2E and 2F.The 2020 Winter CMTA Report
Be the Change: From attitude to exercise to research, in 2020 our CMTA family is committed to be the change we want to see in the world of CMT.
